Pilot study to test the efficacy and safety of activated recombinant factor VII (NovoSeven) in the treatment of refractory hemorrhagic cystitis following high-dose chemotherapy.
Ashrani
A A
AA
Gabriel
D A
DA
Gajewski
J L
JL
Jacobs
D R
DR
Weisdorf
D J
DJ
Key
N S
NS
D000293:Adolescent; D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003556:Cystitis / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000652:urine; D005167:Factor VII / Q000008:administration & dosage* / Q000009:adverse effects; D015942:Factor VIIa; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors
D018906:Antineoplastic Agents, Alkylating; D011994:Recombinant Proteins; D003520:Cyclophosphamide; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa